Endonovo Therapeutics (ENDV) Share-based Compensation (2018 - 2023)
Endonovo Therapeutics has reported Share-based Compensation over the past 12 years, most recently at $194966.0 for Q3 2023.
- Quarterly results put Share-based Compensation at $194966.0 for Q3 2023, up 115.21% from a year ago — trailing twelve months through Sep 2023 was $245966.0 (up 120.38% YoY), and the annual figure for FY2022 was $45000.0, down 52.76%.
- Share-based Compensation for Q3 2023 was $194966.0 at Endonovo Therapeutics, up from -$47123.0 in the prior quarter.
- Over the last five years, Share-based Compensation for ENDV hit a ceiling of $344568.0 in Q3 2020 and a floor of -$1.3 million in Q3 2022.
- Median Share-based Compensation over the past 5 years was $31580.0 (2019), compared with a mean of -$43039.5.
- Biggest five-year swings in Share-based Compensation: skyrocketed 1616.78% in 2020 and later tumbled 2461.25% in 2022.
- Endonovo Therapeutics' Share-based Compensation stood at $169420.0 in 2019, then crashed by 302.28% to -$342708.0 in 2020, then soared by 115.84% to $54289.0 in 2021, then dropped by 17.11% to $45000.0 in 2022, then surged by 333.26% to $194966.0 in 2023.
- The last three reported values for Share-based Compensation were $194966.0 (Q3 2023), -$47123.0 (Q2 2023), and $53123.0 (Q1 2023) per Business Quant data.